Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics , a clinical-stage drug discovery and development company focusing on novel...
COVID-19
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the...
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Update on First BioNTainer for African-based mRNA Manufacturing Facility
MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable...
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows...
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities – – Plan to Dose Additional Participants...
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29
Phase 3, registrational studies remain on track for first half of 2023 topline data readoutSCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE...
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development,...
IGC Announces Updated Life Sciences Presentation
POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today...
Shineco, Inc. Subsidiary Receives Prior Approval Supplement from the NMPA Jiangsu Bureau for the Marketing Approval of “Cardiac 5-Minute Test”
BEIJING, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of...
Altamira Therapeutics Provides Year-End 2022 Business Update
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture...
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy...
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO roleBURLINGTON, Mass., Dec. 19, 2022...
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached...
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE)...
ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices...
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results...
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology...
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Glofitamab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other...